ELI LILLY AND COMPANY Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31)
ELI LILLY AND COMPANY (LLY) reported Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) of $100.00 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-04-26.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeNet · last filed 2013-04-26
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $100.00K.
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2012-09-30 was -$23.70M.
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2012-06-30 was $18.00M, a 13.04% decline year-over-year.
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for the quarter ending 2012-03-31 was -$32.80M, a 209.33% decline year-over-year.
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for fiscal 2011 was -$35.80M, a 136.76% decline from fiscal 2010.
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for fiscal 2010 was $97.40M, a 711.67% increase from fiscal 2009.
- ELI LILLY AND COMPANY derivative instruments, gain (loss) recognized in income, net (deprecated 2013-01-31) for fiscal 2009 was $12.00M.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 3 month | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 6 month | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 9 month | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 12 month | Derivative Instruments, Gain (Loss) Recognized in Income, Net (Deprecated 2013-01-31) 12 month as first filed |
|---|---|---|---|---|---|
| 2013-03-31 | $100.00K 10-Q · filed 2013-04-26 | ||||
| 2012-09-30 | -$23.70M 10-Q · filed 2012-10-26 | -$5.70M derived: sum of 2 quarters · filed 2012-10-26 | -$38.50M 10-Q · filed 2012-10-26 | -$73.30M derived: sum of 4 quarters · filed 2013-04-26 | |
| 2012-06-30 | $18.00M 10-Q · filed 2012-07-27 | -$14.80M 10-Q · filed 2012-07-27 | -$49.60M derived: sum of 3 quarters · filed 2013-04-26 | -$101.30M derived: sum of 4 quarters · filed 2013-04-26 | |
| 2012-03-31 | -$32.80M 10-Q · filed 2013-04-26 | -$67.60M derived: sum of 2 quarters · filed 2013-04-26 | -$119.30M derived: sum of 3 quarters · filed 2013-04-26 | -$98.60M derived: sum of 4 quarters · filed 2013-04-26 | |
| 2011-12-31 | -$34.80M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | -$86.50M derived: sum of 2 quarters · filed 2013-02-21 | -$65.80M derived: sum of 3 quarters · filed 2013-02-21 | -$35.80M 10-K · filed 2013-02-21 | $97.40M 10-K · filed 2012-02-24 |
| 2011-09-30 | -$51.70M 10-Q · filed 2012-10-26 | -$31.00M derived: sum of 2 quarters · filed 2012-10-26 | -$1.00M 10-Q · filed 2012-10-26 | $122.50M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2011-06-30 | $20.70M 10-Q · filed 2012-07-27 | $50.70M 10-Q · filed 2012-07-27 | $174.20M derived: sum of 3 quarters · filed 2013-02-21 | $194.50M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2011-03-31 | $30.00M 10-Q · filed 2012-04-30 | $153.50M derived: sum of 2 quarters · filed 2013-02-21 | $173.80M derived: sum of 3 quarters · filed 2013-02-21 | $124.40M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2010-12-31 | $123.50M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $143.80M derived: sum of 2 quarters · filed 2013-02-21 | $94.40M derived: sum of 3 quarters · filed 2013-02-21 | $97.40M 10-K · filed 2013-02-21 | $12.00M 10-K · filed 2011-02-22 |
| 2010-09-30 | $20.30M 10-Q · filed 2011-10-28 | -$29.10M derived: sum of 2 quarters · filed 2011-10-28 | -$26.10M 10-Q · filed 2011-10-28 | -$85.90M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2010-06-30 | -$49.40M 10-Q · filed 2011-07-29 | -$46.40M 10-Q · filed 2011-07-29 | -$106.20M derived: sum of 3 quarters · filed 2013-02-21 | -$28.60M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2010-03-31 | $3.00M 10-Q · filed 2011-04-29 | -$56.80M derived: sum of 2 quarters · filed 2013-02-21 | $20.80M derived: sum of 3 quarters · filed 2013-02-21 | $27.60M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2009-12-31 | -$59.80M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $17.80M derived: sum of 2 quarters · filed 2013-02-21 | $24.60M derived: sum of 3 quarters · filed 2013-02-21 | $12.00M 10-K · filed 2013-02-21 | $82.60M 10-K · filed 2011-02-22 |
| 2009-09-30 | $77.60M 10-Q · filed 2010-10-29 | $84.40M derived: sum of 2 quarters · filed 2010-10-29 | $71.80M 10-Q · filed 2010-10-29 | ||
| 2009-06-30 | $6.80M 10-Q/A · filed 2010-08-02 | $5.80M 10-Q/A · filed 2010-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |